Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Silencing of CD133 inhibits GLUT1-mediated glucose transport through downregulation of the HER3/Akt/mTOR pathway in colon cancer.
|
31736063 |
2020 |
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results revealed a significant association between Her3 overexpression and tumor differentiation [OR = 2.38; 95% confidence interval (95% CI): 1.76-3.22; P < .001], TNM tumor stage (OR = 0.71; 95% CI: 0.53-0.96; P = .03), and position of colon cancer (OR = 1.71; 95% CI: 1.28-2.27; P < .001).
|
30212974 |
2018 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest a new strategy of therapy for HER3-overexpressing colon cancers.
|
29312543 |
2017 |
Malignant tumor of colon
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our findings suggest that targeting ErbB-3 receptors could represent an effective therapeutic approach in BRAF-V600E mutant colon cancer.
|
26160848 |
2015 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that ERBB3 is a potential target for EGFR- and ERBB2-resistant colon cancer therapy.
|
24970817 |
2014 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a kinome-centered synthetic lethality screen, we find that suppression of the ERBB3 receptor tyrosine kinase sensitizes KRAS mutant lung and colon cancer cells to MEK inhibitors.
|
24685132 |
2014 |
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.
|
22485250 |
2012 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the importance of HER3 in colon cancer and its putative prognostic significance is still unknown.
|
22142822 |
2012 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consistent with the mouse data, which suggest that ERBB3-ERBB4 heterodimers contribute to colon cancer survival, experimentally induced loss of ERBB3 in a KRAS mutant human colon cancer cell line was associated with loss of ERBB4 expression, and siRNA knockdown of either ERBB3 or ERBB4 resulted in elevated levels of apoptosis.
|
19690388 |
2009 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
ErbB2 and ErbB3 receptor tyrosine kinases have been associated with the development of human colon cancer, and the expressions of both receptors are high in HT-29 cells.
|
15741050 |
2005 |
Malignant tumor of colon
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We previously reported that in the HT29 human colon cancer cell line EGCG, the major biologically active component of green tea, inhibits activation of the RTKs EGFR, HER2, and HER3, and that this is associated with inhibition of multiple downstream signaling pathways.
|
16053920 |
2005 |
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings indicate that erbB2 and erbB3, but not EGFR, may contribute to tumor growth and disease progression in colon cancer.
|
9712416 |
1998 |